INTECH Investment Management’s Cytek Biosciences CTKB Stock Holding History

INTECH Investment Management’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$114K	Buy	25,633 +4	+0%	+$17	﹤0.01%	1924
2026 Q1	$112K	Sell	25,629 -26,111	-50%	-$123K	﹤0.01%	1873
2025 Q4	$261K	Buy	51,740 +3,242	+7%	+$15.1K	﹤0.01%	1834
2025 Q3	$168K	Buy	48,498 +1,556	+3%	+$5.84K	﹤0.01%	2125
2025 Q2	$160K	Sell	46,942 -20,923	-31%	-$69.7K	﹤0.01%	2163
2025 Q1	$272K	Buy	67,865 +18,161	+37%	+$94.1K	﹤0.01%	1946
2024 Q4	$323K	Buy	49,704 +26,567	+115%	+$158K	﹤0.01%	1801
2024 Q3	$128K	Buy	+23,137	New	+$131K	﹤0.01%	1839

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

INTECH Investment Management's CTKB Position: Q2 2026 in Review

INTECH Investment Management increased its Cytek Biosciences (CTKB) stake by 0.02% in Q2 2026, buying an estimated $17 and bringing the position to 25,633 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #1924.

INTECH Investment Management first reported a position in CTKB in Q3 2024 and has held it in 8 quarters since. The position peaked at $323K in Q4 2024. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

INTECH Investment Management held 25,633 shares of Cytek Biosciences worth $114K as of Q2 2026.
INTECH Investment Management bought 4 Cytek Biosciences shares in Q2 2026, an estimated $17.
Cytek Biosciences made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1924 holding.
INTECH Investment Management first reported a position in Cytek Biosciences in Q3 2024 and has held it in 8 quarters since.
INTECH Investment Management's Cytek Biosciences position peaked at $323K in Q4 2024.
154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.